MAP2K7 and central serous retinopathy: Although there have been reports of central serous retinopathy associated with binimetinib and other MEK and PKC inhibitors (23), in our study only 5.3% (2/38) of patients experienced retinopathy regardless of causality and no grade 3 or 4 events were observed.